Today's Research Reports on Stocks to Watch: NeuroDerm and Exact Sciences
NEW YORK, NY / ACCESSWIRE / June 1, 2017 / NeuroDerm was one of the biggest winners on the NASDAQ despite any significant news, aside from traders perhaps anticipating next week's 21st International Congress of Parkinson's Disease and Movement Disorders where the company will showcase data from an important trial regarding ND0612H which is a treatment for severe stage Parkinson's disease patients. Exact Sciences also scored big on Wednesday after UnitedHealth Group said it would cover the company's colon testing starting July 1st.
RDI Initiates Coverage on:
NeuroDerm Ltd.
https://ub.rdinvesting.com/news/?ticker=NDRM
Exact Sciences Corporation
https://ub.rdinvesting.com/news/?ticker=EXAS
NeuroDerm Ltd.'s shares rallied yesterday to a tremendous close in the green. The stock closed up 17.78% on higher volume than usual, despite no significant news to explain the move. The company did announce last week that complete data from the clinical stage pharma company's trial 006 would be showcased in a late-breaking poster session next week at the 21st International Congress of Parkinson's Disease and Movement Disorders in Vancouver. The event will be held from June 4th to June 8th. The company's Trial 006 was an international open label, blinded rater, phase II study of ND0612H, NeuroDerm's high dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation, in patients with advanced Parkinson's disease. NeuroDerm is developing ND0612H for the treatment of severe stage Parkinson's disease patients for whom oral drugs are no longer effective.
Access RDI's NeuroDerm Research Report at:
https://ub.rdinvesting.com/news/?ticker=NDRM
Exact Sciences Corporation's shares were on a gaining frenzy on Wednesday, closing up 11.70% and even hitting a new high of $36.61 in intra-day trading. Traders were very excited to find out that UnitedHealth Group Inc. said it plans to cover Exact Science's colon cancer test starting on July 1. Much of the excitement had to do with the fact that short seller Citron Research alleged earlier this month that the company wouldn't ever get covered by UnitedHealth Group for the test. Looks like Citron Research is now eating their words. Analyst Mark Massaro from Canaccord Genuity commented that the test was, "another major win for EXAS, a coverage decision that comes in nearly a year before we expected." The firm estimates that UNH will add around 30 million covered lives for Cologuard, which brings the total number of lives covering Cologuard to approximately 227 million. Massaro has a buy rating on the stock and raised his target from $38 to $40. Shares of Exact Sciences have been on a rampage in the last three months, with gains of over 50%.
Access RDI's Exact Sciences Research Report at:
https://ub.rdinvesting.com/news/?ticker=EXAS
Our Actionable Research on NeuroDerm Ltd. (NASDAQ: NDRM) and Exact Sciences Corporation (NASDAQ: EXAS) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
